Formulation for cultivating dendritic killer cells and method using the same

1. A method for cultivating dendritic killer cells, comprising the following steps:

(a) obtaining a peripheral blood mononuclear cell population from human blood;

(b) adding an effective amount of IL-15 and IL-12 to the peripheral blood mononuclear cell population, to make the concentration of IL-15 greater than 1 ng/mL, and to make the concentration of IL-12 between 0.5-20 ng/mL;

(c) culturing the cells for a first appropriate period: and

(d) sorting the dendritic killer cells, wherein the dendritic killer cells are cells with the surface marker HLA-G − CD14 − CD19 − CD3 − CD56 + HLA-DR + .

2. The method according to claim 1 , wherein the concentration of IL-15 is 10 ng/mL.

3. The method according to claim 1 , wherein between said step (c) and said step (d), said method further comprises the following steps:

(z1) collecting non-adherent cells;

(z2) spinning down the non-adherent cells to obtain a precipitation;

(z3) re-suspending said precipitation in a formulation comprising an effective amount of IL-15 and IL-12; and

(z4) culturing the re-suspended precipitation for a second appropriate period.

4. The method according to claim 1 wherein between the step (a) and the step (b), the method further comprises the following step:

(x) depleting CD3 + cells and CD19 + cells from the human peripheral blood mononuclear cells.

5. The method according to claim 1 , wherein after the step

(d), the number of the dendritic killer cell population increases 200-fold to 400-fold compared to its number in step (a).

6. The method according to claim 1 , wherein the step (a) further comprises the following steps:

(a1) collecting the human blood;

(a2) sorting the peripheral blood mononuclear cell population from the human blood; and

(a3) removing T cells and B cells from the peripheral blood mononuclear cell population.

7. The method according to claim 6 , wherein the human blood in the step (a1) is obtained from a cancer patient.

8. The method according to claim 7 , wherein the cancer patient suffers from a cancer, and the cancer can be selected from a group consisting of squamous cell carcinoma, lobular carcinoma in situ, liver cancer, nasopharyngeal carcinoma, lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancers, malignant melanoma, cervical cancer, ovarian cancer, colon cancer, anal cancer, stomach cancer, breast cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, esophageal cancer, thyroid cancer, adrenal cancer, cancers of mesothelial and soft tissue, urethra cancer, cancer of penis, prostate cancer, acute leukemia, chronic leukemia, lymphomas, bladder cancer, ureteral cancer, renal cell carcinoma, urothelial carcinoma, cancer of central nervous system, primary central nervous system lymphoma, glioma, pituitary tumor, Kaposi's sarcoma, squamous cell cancer and their metastasis.

9. A method of obtaining an enriched population of human dendritic killer cells, the method comprising:

(a) obtaining human peripheral blood mononuclear cells (PBMCs), and in line 7 0.5˜20;

(b) depleting CD3 + cells and CD19 + cells from the human peripheral blood mononuclear cells to obtain human CD3 − CD19 − PBMCs:

(c) culturing the human CD3 − CD19 − PBMCs in a medium containing IL-15 and 0.5-20 ng/mL IL-12;

(d) isolating non-adherent cells to obtain a dendritic killer cell-enriched cell population; and

(e) sorting the dendritic killer cells from the dendriitic killer cell-enriched cell population, wherein the dendritic killer cells are cells with the surface marker HLA-G − CD14 − CD19 − CD3 − CD56 + HLA-DR + .

10. The method according to claim 9 , wherein the concentration of IL-15 is 10 ng/mL.

11. The method according to claim 9 , wherein the human peripheral blood mononuclear cells are collected from a cancer patient.